BIAFNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAFW
bioAffinity Technologies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.51−0.22 (-5.90%)
Close on Oct 19, 2026
- Market cap
- $18.35M
- P/E (TTM)
- –
- Dividend yield
- –
bioAffinity Technologies, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Laboratory Services [Member] | $6.16M | $9.35M | $2.51M | $4.80K | 100.0% | -34.1% |
| Health Care, Patient Service [Member] | $4.97M | $8.18M | $2.20M | – | 80.7% | -39.2% |
| Histology Service Fees [Member] | $1.12M | $1.10M | $272.66K | – | 18.1% | +1.2% |
| Medical Director Fees [Member] | $68.27K | $66.58K | $19.32K | – | 1.1% | +2.5% |
| Other Revenues [Member] | $4.86K | $7.37K | $21.52K | $4.80K | 0.1% | -34.1% |
| Diagnostic R&D [Member] | $577 | $8.65K | $19.44K | – | 0.0% | -93.3% |
| Department of Defense Observational Studies [Member] | $577 | $8.65K | $19.44K | – | 0.0% | -93.3% |
| Department Of Defense Observational Studiesr [Member] | – | – | $19.44K | – | – | – |
| Histology Fees [Member] | – | – | $272.66K | – | – | – |
| Health Care, Other [Member] | – | – | $19.32K | – | – | – |
By region
From the segment and revenue-disaggregation notes of bioAffinity Technologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.